fosdagrocorat

Fosdagrocorat is a nonsteroidal, steroid-like selective glucocorticoid receptor modulator (SGRM) developed as a prodrug of dagrocorat to improve pharmacokinetics. It acts as a dissociated agonist (partial agonist) of the glucocorticoid receptor, aiming to retain anti-inflammatory efficacy while reducing adverse effects typically associated with traditional glucocorticoids. Fosdagrocorat was investigated for the treatment of rheumatoid arthritis and reached phase II clinical trials before its development was discontinued. The drug was designed to enhance transrepression-mediated anti-inflammatory effects over transactivation-mediated side effects, potentially offering improved safety compared to standard glucocorticoids like prednisone. Pfizer led its development[1][2][3][4][5].

Other names

dagrocorat 2-(dihydrogen phosphate)dagrocorat dihydrogen phosphate